The study investigated the efficacy of antibiotic bone cement for infected diabetic foot wounds. The study found that antibiotic cement gave promising results for the management of diabetic foot-infected wounds.

The study investigated the effectiveness and safety of abatacept (Orencia) for patients with rheumatoid arthritis (RA). The analysis concluded that abatacept gave better results to patients with RA compared to other biologic drugs. 

This study examined the impact of three types of aerobic training exercises on measurements of heart and metabolic function in patients with type 2 diabetes (T2D). The data showed that greater improvements occurred in heart and breathing function measurements with low-volume high-intensity training (HITT) compared to low-volume moderate to vigorous intensity continuous training (MICT) in these patients.

This study investigated the effects of foot-ankle therapeutic exercises on daily physical activity and gait (walking) speed in people with diabetic peripheral neuropathy (DPN). The data showed that at 12 weeks, these exercises led to improvements in fast walking speeds and quality of life compared to usual care.

This study assessed the effectiveness and safety of adding dorzagliatin (HMS552) to metformin therapy in patients with type 2 diabetes (T2D) with inadequately controlled blood glucose (sugar) while using metformin (Glucophage) alone. The data showed effective blood glucose control, good tolerance, and safety in patients treated with dorzagliatin and metformin.

This study evaluated the effectiveness and long-term safety of dorzagliatin in patients with type 2 diabetes (T2D) without previous antidiabetic treatment. The authors concluded that dorzagliatin blood glucose (sugar) levels with no serious side effects in these patients. 

This study analyzed the safety and effectiveness of dapagliflozin (Farxiga) in patients with type 2 diabetes (T2D) across different ranges of baseline systolic blood pressure (SBP; blood pressure when the heart beats). The data suggested that dapagliflozin reduced the risk of hospitalization for heart failure (HHF) and kidney-related outcomes and was safe for use across different levels of SBP without causing an increase in short-term (acute) kidney injury, dehydration, or amputations in patients.

This study investigated the link between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and eye (ocular) diseases in patients with type 2 diabetes (T2D). The data showed that there was no link between the occurrence of eye diseases and SGLT2is in these patients. Some SGLT2is such as ertugliflozin (Steglatro) and empagliflozin (Jardiance) may protect against eye disease while canagliflozin (Invokana) may promote eye disease. 

This review assessed the effects of new glucose-lowering drugs on stroke risk in patients with type 2 diabetes (T2D). The study showed that glucagon-like peptide-1 receptor (GLP-1) agonists are potentially beneficial for stroke risk in patients with T2D.

This review analyzed the effectiveness and safety of nutrient supplements for the control of blood glucose and insulin resistance in patients with type 2 diabetes (T2D). The authors concluded that there is currently a lack of sufficient clinical evidence to support the use of nutrient supplements for blood glucose control and improved insulin resistance in these patients.